This review discusses how advances in formulation and device design can be utilized to
dramatically improve lung targeting and dose consistency relative to current marketed dry …

Impressive advances in inhalation therapy for patients with asthma and chronic obstructive
pulmonary disease (COPD) have occurred in recent years. However, important gaps in care …

Pulmonary drug delivery is the promising delivery route to treat not only respiratory diseases
but also systemic diseases and has proven as a potential delivery route for complex drugs …

This brief overview of the factors determining lung deposition of aerosols provides
background information required by health care providers when instructing patients to use …

Background Although understanding of the scientific basis of aerosol therapy with dry
powder inhalers (DPIs) has increased, some misconceptions still persist. These include the …

Technologies for long-term delivery of aerosol medications in asthma and chronic
obstructive pulmonary disease have improved over the past 2 decades with advancements …

Appropriate selection and correct use of inhalation devices is an integral component in the
management of asthma and chronic obstructive pulmonary disease (COPD). It is well known …

Introduction: The number of pulmonary diseases that are effectively treated by aerosolized
medicine continues to grow. Areas covered: These diseases include chronic obstructive …

Dosimetry, safety and the efficacy of drugs in the lungs are critical factors in the development
of inhaled medicines. This article considers the challenges in each of these areas with …

In the last decades, dry powder inhalation has become a very attractive option for pulmonary
drug delivery to treat lung diseases like cystic fibroses and lung infections. In contrast to the …